Logo image of NUVA

NUVASIVE INC (NUVA) Stock Fundamental Analysis

NASDAQ:NUVA - US6707041058 - Common Stock

39.75 USD
-0.91 (-2.24%)
Last: 8/31/2023, 8:10:26 PM
39.88 USD
+0.13 (+0.33%)
After Hours: 8/31/2023, 8:10:26 PM
Fundamental Rating

4

NUVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. NUVA has a medium profitability rating, but doesn't score so well on its financial health evaluation. NUVA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year NUVA was profitable.
NUVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NUVA reported negative net income in multiple years.
NUVA had a positive operating cash flow in each of the past 5 years.
NUVA Yearly Net Income VS EBIT VS OCF VS FCFNUVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M 200M

1.2 Ratios

NUVA has a better Return On Assets (1.36%) than 75.38% of its industry peers.
NUVA has a Return On Equity of 3.19%. This is in the better half of the industry: NUVA outperforms 76.38% of its industry peers.
NUVA's Return On Invested Capital of 3.43% is fine compared to the rest of the industry. NUVA outperforms 76.38% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NUVA is significantly below the industry average of 8.18%.
The 3 year average ROIC (2.87%) for NUVA is below the current ROIC(3.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROIC 3.43%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
NUVA Yearly ROA, ROE, ROICNUVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5 -5 10

1.3 Margins

NUVA has a Profit Margin of 2.32%. This is in the better half of the industry: NUVA outperforms 74.37% of its industry peers.
NUVA's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 6.73%, NUVA is doing good in the industry, outperforming 74.87% of the companies in the same industry.
NUVA's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 71.66%, NUVA belongs to the top of the industry, outperforming 82.41% of the companies in the same industry.
In the last couple of years the Gross Margin of NUVA has remained more or less at the same level.
Industry RankSector Rank
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
NUVA Yearly Profit, Operating, Gross MarginsNUVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NUVA is destroying value.
The number of shares outstanding for NUVA has been increased compared to 1 year ago.
NUVA has a better debt/assets ratio than last year.
NUVA Yearly Shares OutstandingNUVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NUVA Yearly Total Debt VS Total AssetsNUVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 1.91 indicates that NUVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of NUVA (1.91) is comparable to the rest of the industry.
NUVA has a Debt/Equity ratio of 0.89. This is a neutral value indicating NUVA is somewhat dependend on debt financing.
NUVA's Debt to Equity ratio of 0.89 is on the low side compared to the rest of the industry. NUVA is outperformed by 78.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z 1.91
ROIC/WACC0.42
WACC8.11%
NUVA Yearly LT Debt VS Equity VS FCFNUVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M 400M 600M 800M

2.3 Liquidity

NUVA has a Current Ratio of 1.25. This is a normal value and indicates that NUVA is financially healthy and should not expect problems in meeting its short term obligations.
NUVA has a Current ratio of 1.25. This is amonst the worse of the industry: NUVA underperforms 89.45% of its industry peers.
NUVA has a Quick Ratio of 1.25. This is a bad value and indicates that NUVA is not financially healthy enough and could expect problems in meeting its short term obligations.
NUVA has a Quick ratio of 0.65. This is amonst the worse of the industry: NUVA underperforms 93.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 0.65
NUVA Yearly Current Assets VS Current LiabilitesNUVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.61% over the past year.
The Earnings Per Share has been growing slightly by 0.62% on average over the past years.
NUVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.44%.
The Revenue has been growing slightly by 3.20% on average over the past years.
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%

3.2 Future

The Earnings Per Share is expected to grow by 14.32% on average over the next years. This is quite good.
NUVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NUVA Yearly Revenue VS EstimatesNUVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
NUVA Yearly EPS VS EstimatesNUVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 19.88, which indicates a rather expensive current valuation of NUVA.
NUVA's Price/Earnings ratio is rather cheap when compared to the industry. NUVA is cheaper than 86.93% of the companies in the same industry.
When comparing the Price/Earnings ratio of NUVA to the average of the S&P500 Index (27.24), we can say NUVA is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 15.23, the valuation of NUVA can be described as correct.
Based on the Price/Forward Earnings ratio, NUVA is valued cheaper than 88.44% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.82, NUVA is valued rather cheaply.
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
NUVA Price Earnings VS Forward Price EarningsNUVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NUVA is valued cheaper than 93.47% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11
NUVA Per share dataNUVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

NUVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NUVA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NUVA's earnings are expected to grow with 14.90% in the coming years.
PEG (NY)1.42
PEG (5Y)32.2
EPS Next 2Y14.82%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

NUVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVASIVE INC

NASDAQ:NUVA (8/31/2023, 8:10:26 PM)

After market: 39.88 +0.13 (+0.33%)

39.75

-0.91 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-02 2023-08-02/amc
Earnings (Next)11-07 2023-11-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change0%
Market Cap2.08B
Analysts70.91
Price Target50.72 (27.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.04%
Min EPS beat(2)0.41%
Max EPS beat(2)7.68%
EPS beat(4)2
Avg EPS beat(4)-2.68%
Min EPS beat(4)-17.19%
Max EPS beat(4)7.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.05%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)1.16%
Revenue beat(4)1
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.53%
PT rev (3m)2.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
P/S 1.7
P/FCF N/A
P/OCF 14.94
P/B 2.34
P/tB 24.74
EV/EBITDA 11
EPS(TTM)2
EY5.03%
EPS(NY)2.61
Fwd EY6.57%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)2.66
OCFY6.69%
SpS23.38
BVpS17.02
TBVpS1.61
PEG (NY)1.42
PEG (5Y)32.2
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROCE 5.48%
ROIC 3.43%
ROICexc 3.59%
ROICexgc 6.59%
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
ROICexc(3y)4.12%
ROICexc(5y)4.87%
ROICexgc(3y)17.94%
ROICexgc(5y)16.07%
ROCE(3y)3.71%
ROCE(5y)5.01%
ROICexcg growth 3Y3.59%
ROICexcg growth 5Y-1.31%
ROICexc growth 3Y-7.11%
ROICexc growth 5Y-4.99%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA 3.58
Cap/Depr 101.93%
Cap/Sales 11.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 0.65
Altman-Z 1.91
F-Score7
WACC8.11%
ROIC/WACC0.42
Cap/Depr(3y)82.61%
Cap/Depr(5y)85.69%
Cap/Sales(3y)10.64%
Cap/Sales(5y)10.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%
EBIT growth 1Y45.07%
EBIT growth 3Y-11.68%
EBIT growth 5Y-7.06%
EBIT Next Year96.6%
EBIT Next 3Y33.66%
EBIT Next 5Y25.87%
FCF growth 1Y-102.72%
FCF growth 3Y-34.34%
FCF growth 5Y-14.37%
OCF growth 1Y-39.92%
OCF growth 3Y-10.42%
OCF growth 5Y-0.91%